Analysed TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) News Sources
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
17-09-2026
yahoo.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
23-09-2026
yahoo.com
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
02-10-2026
yahoo.com
Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed
07-10-2026
yahoo.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12-10-2026
yahoo.com
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
23-10-2026
yahoo.com
What is the current price of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The current price of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is $49.94.
TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) since the previous trading day is $-0.03.
TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) since the previous trading day is -0.06%.
What is the most recent average sentiment score for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The most recent average sentiment score for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is 62 out of 100.
What is the most recent average sentiment for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)?
The most recent sentiment for TRAVERE THERAPEUTICS INC (TVTX:NASDAQ) is .
SEC-8K** Filing Available For TRAVERE THERAPEUTICS INC (TVTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.